FDA Safety Updates to Antiretroviral Labels

摘要

On 27 May 2010, the FDA approved changes to the labeling for maraviroc (Celsentri/Selzentry) 150 mg and 300 mg tablets to include:Dosing recommendations for patients with renal impairment,A contraindication for patients with severe renal impairment or end-stage renal disease,A warning regarding postural hypotension for renal impaired patients,New pharmacokinetics information related to renal impairment.